Latest Commercial Revenue News

Page 4 of 8
Brisbane Broncos expect a 33% increase in half-year net profit before tax to $11.57 million, driven by higher crowd attendance and merchandise sales despite reduced ARLC funding and rising costs.
Victor Sage
Victor Sage
18 Aug 2026
Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.
Ada Torres
Ada Torres
21 July 2026
Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.
Ada Torres
Ada Torres
13 July 2026
Brisbane Broncos capped a landmark 2025 season with both NRL and NRLW premiership victories, driving a 20.5% revenue surge and a 36% profit increase. The club rewarded shareholders with increased dividends amid record crowds and expanded community programs.
Victor Sage
Victor Sage
19 May 2026
NoviqTech (ASX: NVQ) advances its biochar carbon removal strategy with a key non-binding MoU covering 70% of credits from its Great Barrier Reef project, targeting 2026 commercial milestones.
Maxwell Dee
Maxwell Dee
7 May 2026
Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.
Ada Torres
Ada Torres
30 Apr 2026
Tlou Energy has crossed a significant threshold by generating initial revenue from its Lesedi coal bed methane gas through the newly operational Kala Data Centre in Botswana. The milestone validates its integrated gas-to-power model while funding constraints and technical challenges remain key hurdles.
Maxwell Dee
Maxwell Dee
24 Apr 2026
Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.
Ada Torres
Ada Torres
27 Feb 2026
Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.
Ada Torres
Ada Torres
27 Feb 2026
Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.
Ada Torres
Ada Torres
25 Feb 2026
Winton Land Limited reports a sharp 60% revenue decline in its interim results for H1 FY26 but narrows its net loss and progresses key development projects amid a cautious economic backdrop.
Eva Park
Eva Park
20 Feb 2026
Tlou Energy has commissioned its Kala Data Centre in Botswana, marking the first commercial revenue from its Coal Bed Methane gas resources and validating its integrated gas-to-power strategy.
Maxwell Dee
Maxwell Dee
19 Feb 2026

Browse the archive

Full archive